GlassScriptPhysician profile
Howard B Hamat
NPI 1376537605
$16,953.59
in general payments reported to CMS, 2019-2025
40 companies · $2,306 in 2025
The $2,306 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,713 · 2020: $977 · 2021: $1,231 · 2022: $1,199 · 2023: $2,014 · 2024: $3,514 · 2025: $2,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,925 · Consulting Fee: $1,755 · Education: $138 · Travel and Lodging: $16.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,924.90 |
| Consulting Fee | $1,755.00 |
| Education | $138.00 |
| Travel and Lodging | $16.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,802.22 | 2019-2025 | Entyvio |
| Abbvie INC. | $2,389.24 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,645.30 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,060.12 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Gilead Sciences, INC. | $943.81 | 2022-2025 | Livdelzi |
| Celgene Corporation | $662.75 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $641.92 | 2019-2025 | Stelara, Tremfya, Remicade |
| Stryker Corporation | $560.00 | 2020 | |
| Biogen, INC. | $450.00 | 2019-2023 | Tysabri |
| Pfizer INC. | $413.27 | 2021-2025 | |
| Medtronic, INC. | $338.64 | 2022-2025 | Interstim, Pillcam |
| Intercept Pharmaceuticals, INC. | $280.33 | 2019-2025 | Ocaliva |
| Celltrion USA INC. | $276.55 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $225.17 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $160.64 | 2021-2024 | Rebyota |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $127.17 | 2021-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $103.34 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $87.75 | 2023-2025 | Omvoh |
| Evoke Pharma, INC. | $69.67 | 2023-2024 | Gimoti |
| Nestle Healthcare Nutrition INC. | $62.18 | 2021-2022 | |
| Braintree Laboratories, INC. | $59.91 | 2021-2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $59.43 | 2025 | Vowst |
| Vivus LLC | $56.41 | 2021-2025 | Pancreaze |
| Biocon Biologics INC | $56.32 | 2024-2025 | Yesintek, Hulio |
| Astrazeneca Pharmaceuticals LP | $46.23 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $40.89 | 2025 | Iqirvo |
| Amgen INC. | $39.87 | 2020-2025 | |
| Romark Laboratories, Lc | $39.51 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.22 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $38.62 | 2021 | |
| Ardelyx, INC. | $36.16 | 2023-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $33.81 | 2023-2024 | Dificid, Zinplava |
| Eton Pharmaceuticals, INC. | $24.40 | 2025 | Betaine Anhydrous, Nitisinone, Carglumic Acid |
| Shionogi INC | $15.93 | 2019 | |
| Novo Nordisk INC | $15.42 | 2025 | Wegovy |
| Conmed Corporation | $14.84 | 2023 | Conmed Generators |
| Intra-Sana Laboratories | $14.72 | 2022 | |
| Madrigal Pharmaceuticals | $14.31 | 2025 | Rezdiffra |
| Organon LLC | $7.52 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Hamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.